Clinical trials: Prostate Cancer Aggressiveness
Prostate Cancer, Genetic Predisposition
Prostate Tissue BioBank
Prostate cancer is also the most common cancer in men with inherited pathogenic variants in BRCA1 and BRCA2. Beyond BRCA1/2, other genes are known to increase the risk of prostate cancer, including ATM, TP53 and HOXB13.
- Trial name
- PTBB (NCT06659614)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Prostate Cancer
Early Salvage Therapy for Patients With Advanced Features for Biochemical Relapse After Radical Prostatectomy for Localized Prostate Carcinoma In Correlation With Supposed Molecular-genetic Parameters of Higher Aggressiveness
The primary objective of the trial is to compare the impact and safety of delayed salvage therapy (dSRT, i.e., SRT initiated at PSA values of 0.4-0.5 ng/ml) to those of early salvage therapy (eSRT, i.e., at PSA levels of 0.2…
- Trial name
- ESTABLISH (NCT05232578)
- Testing
- Early salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT)
- Volunteers
- 380 people
- Sponsor
- General University Hospital, Prague
Prostatic Neoplasms, Genital Neoplasms, Male
MRI for Assessment of Hypoxia-Induced Prostate Cancer Aggressiveness
The purpose of the study is to combine and correlate data from morphological and functional MRI, molecular signatures of tumor hypoxia, the presence of micrometastases and tumor hypoxia with the goal being predicting of prostate…
- Conditions
- Prostatic Neoplasms, Genital Neoplasms, Male, Prostatic Diseases
- Trial name
- FuncProst (NCT01464216)
- Where
- Norway
- Volunteers
- 120 people
- Sponsor
- Oslo University Hospital
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Aggressive Variant Prostate Carcinoma
Zanzalintinib in Men With Aggressive Variant Prostate Cancer
This is a multi-center single arm phase II study to evaluate the antitumor activity of zanzalintinib 60mg orally (PO) once daily in subjects with AVPC.
- Trial name
- NAPOLEON (NCT07218666)
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Deepak Kilari
Metastatic Castration-Resistant Prostate Cancer
XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer…
- Trial name
- NCT05005728
- Testing
- vudalimab + carboplatin + cabazitaxel, vudalimab + olaparib, vudalimab monotherapy
- Where
- 26 sites in United States
- Volunteers
- 72 people
- Sponsor
- Xencor, Inc.
Prostate Cancer, Obesity
Exercise, Prostate Cancer and Circulating Tumour Cells
Obesity, known to be associated with a pro-inflammatory, pro-thrombotic humoral milieu, confers a worse prognosis in prostate cancer (PrCa). Circulating tumour cells (CTCs) are identified in the blood in advanced cancer.
- Trial name
- ExPeCT (NCT02453139)
- Testing
- Exercise
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 67 people
- Sponsor
- University of Dublin, Trinity College
Prostate Cancer
Magnetic Resonance Spectroscopic Imaging Study of Prostatic Fats to Distinguish the Difference Between High and Low Risk Prostate Cancer
A prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease.
- Trial name
- MRSI+RRP (NCT01780701)
- Testing
- Magnetic Resonance Spectroscopy Imaging with rectal probe
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- OHSU Knight Cancer Institute
Prostate Cancer
A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery
Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive disease features will receive salvage radiation therapy and standard androgen deprivation therapy (ADT) or enhanced ADT to determine if…
- Trial name
- STEEL (NCT03809000)
- Testing
- Radiation Therapy, Enzalutamide, Bicalutamide
- Where
- 108 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- RTOG Foundation, Inc.
Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer that has spread to other places in…
- Conditions
- Aggressive Variant Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Metastatic Prostate Neuroendocrine Carcinoma
- Trial name
- NCT04592237
- Testing
- Cabazitaxel, Carboplatin, Cetrelimab
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Assessment of Prostate MRI Before Prostate Biopsies
Background: Prostate cancer is difficult to detect using ultrasound. As a result, in case of suspicion of prostate cancer based on digital rectal examination (DRE) or Prostate Specific Antigen (PSA) level, it is currently…
- Trial name
- MRI-FIRST01 (NCT02485379)
- Testing
- Prostate biopsy
- Where
- 20 sites in France
- Volunteers
- 275 people
- Sponsor
- Hospices Civils de Lyon
Decision Support Systems, Clinical, Prostate Cancer
Pioneering Advances in Care and Education (PACE)
This clinical trial evaluates the use of novel decision support educational materials and services using health coaches. The study includes men newly diagnosed with low-risk prostate cancer. A 160 men will be recruited.
- Trial name
- PACE (NCT03397160)
- Testing
- Decision Support Intervention (DSI)
- Where
- 4 sites in United States
- Volunteers
- 119 people
- Sponsor
- University of California, San Francisco
Prostate Cancer
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
- Trial name
- CONCORD (NCT07052578)
- Where
- 28 sites in Russia
- Volunteers
- 230 people
- Sponsor
- AstraZeneca
Prostate Cancer
uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness
Prospective study to evaluate the value of uPAR-targeted PET/MR scan using the tracer 68Ga-NOTA-AE105 in patients with newly diagnosed prostate cancer
- Trial name
- NCT03307460
- Testing
- 68Ga-NOTA-AE105
- Where
- Denmark
- Volunteers
- 52 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Prostate Cancer Aggressiveness, Prostate Carcinoma
Study of Olaparib Maintenance Following Cabazitaxel-Carbo in Men With AVPC
The goal of this clinical research study is to learn if olaparib, when given after treatment with cabazitaxel, carboplatin, and prednisone, can help to control aggressive variant prostate cancer (AVPC).
- Trial name
- NCT03263650
- Testing
- Cabazitaxel, Carboplatin, Prednisone 5Mg
- Where
- United States
- Volunteers
- 96 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer Metastatic
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
It is a Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer.
- Trial name
- PEAPOD_FOS (NCT05563558)
- Testing
- Pembrolizumab, Carboplatin, Cabazitaxel
- Where
- Spain
- Volunteers
- 42 people
- Sponsor
- Fundacion Oncosur
Prostate Cancer, Prostate Adenocarcinoma
Utility of Adding MR Fusion to Standard US Guided Prostate Biopsy
The purpose of this study is to utilize this technology in the early detection and staging of pathologic states within prostate cancer patients using the information obtained on mpMRI and serum biomarkers from the patient's blood…
- Trial name
- NCT05064111
- Testing
- TRUS biopsy
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Arizona
Prostate Cancer
Analyzing the Composition of Tears and Blood for Discovery of Novel Signatures of Aggressive Prostate Cancer
The purpose of this research study is to compare profiles in the blood and tears of patients with and without prostate cancer with the goal of developing a method of separating men with aggressive and non-aggressive disease.
- Trial name
- NCT01514669
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- University of Arkansas
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer
The purpose of this study is to find out what treatment works best for participants with metastatic prostate cancer that are not responding to hormone treatment and docetaxel and are also Prostate-specific membrane antigen(PSMA)…
- Trial name
- CATCH-177 (NCT06738303)
- Testing
- Cabazitaxel and carboplatin, Lu-PSMA-617
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Case Comprehensive Cancer Center
Prostate Cancer, Prostate Intraductal Carcinoma
Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer
The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the…
- Conditions
- Prostate Cancer, Prostate Intraductal Carcinoma, Prostate Cancer Aggressiveness, Prostate Cancer Stage
- Trial name
- NCT06662708
- Testing
- Accurate Prediction Artificial Intelligence Models
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Shao Pengfei